Thoracic Neoplasms  >>  linsitinib (ASP7487)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
linsitinib (ASP7487) / Sling Therap
NCT01221077: Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene

Completed
2
88
Canada, US, RoW
OSI-906, Erlotinib, OSI-774, Tarceva, Placebo
Astellas Pharma Inc
NSCLC, Non Small Cell Lung Cancer
03/13
09/14
NCT01186861 / 2010-020916-12: Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy

Completed
2
205
Canada, US, Europe, RoW
OSI-906, erlotinib, OSI-774, Tarceva, placebo
Astellas Pharma Inc
Non-Small Cell Lung Cancer (NSCLC) With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy
07/13
03/15
NCT01533181: Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung Cancer

Completed
2
44
US, RoW
Laboratory Biomarker Analysis, Linsitinib, IGF-1R inhibitor OSI-906, OSI-906, OSI-906AA, Pharmacological Study, Topotecan Hydrochloride, Hycamptamine, Hycamtin, SKF S-104864-A, Topotecan HCl, topotecan hydrochloride (oral)
National Cancer Institute (NCI)
Recurrent Small Cell Lung Carcinoma
11/14
11/14
NCT01560260: Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors

Checkmark ASCO 2014
May 2014 - May 2014: ASCO 2014
Completed
2
20
US
Laboratory Biomarker Analysis, Linsitinib, IGF-1R inhibitor OSI-906, OSI-906, OSI-906AA, Pharmacological Study
National Cancer Institute (NCI)
Carney Complex, Chondrosarcoma, Gastrointestinal Stromal Tumor, Paraganglioma
10/15
10/15

Download Options